ELISpot & FluoroSpot Assay Market Report 2026-2031: Mabtech, Oxford Immunotec Global, and Cellular Technology Dominate the Landscape

Dublin, March 20, 2026 (GLOBE NEWSWIRE) -- The "ELISpot & FluoroSpot Assay Market Report: Trends, Forecast and Competitive Analysis to 2031" has been added to ResearchAndMarkets.com's offering.

The global ELISpot & FluoroSpot assay market is expected to grow with a CAGR of 7.1% from 2025 to 2031. The major drivers for this market are the increasing adoption of immunology research techniques, the rising focus on personalized immune therapies, and the growing demand for advanced diagnostic assays.

Key Highlights by Segment

• Within the product type category, reagent is expected to witness the highest growth over the forecast period.
• Within the end use category, pharmaceutical & biotechnology firm is expected to witness the highest growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the ELISpot & FluoroSpot Assay Market

The ELISpot & FluoroSpot assay market is experiencing rapid growth driven by advancements in immunological research, diagnostics, and personalized medicine. These trends emphasize technological innovation, integration with other diagnostic tools, and expanding applications across healthcare sectors, which are enhancing assay performance, broadening their accessibility, and transforming immune response analysis.

• Technological Innovation: Automation and digital technologies are revolutionizing assays by improving efficiency, precision, and usability, thereby driving market growth.
• Multiplexing Capabilities: Simultaneous detection of multiple immune markers enhances data richness, particularly valuable in vaccine research and disease monitoring.
• Personalized Medicine and Diagnostics: The trend supports customized therapies by providing patient-specific data, especially in cancer and autoimmune diseases.
• Expanding Application Areas: The adoption in clinical diagnostics, vaccine development, and emerging fields like immuno-oncology is broadening market scope.
• Regulatory and Standardization Advances: Standardized protocols and regulatory approvals ensure reproducibility and boost market integration.

Recent Developments in the ELISpot & FluoroSpot Assay Market

Recent advancements have focused on improving assay sensitivity, automation, and multiplexing, expanding applications and improving efficiency. The increasing use of these assays in clinical diagnostics underscores their growing role in healthcare.

• Advancements in sensitivity and multiplexing offer more comprehensive immune profiling.
• Automation increases throughput and reduces errors, benefitting large-scale studies.
• Increased adoption in clinical settings enhances diagnostic accuracy and patient management.
• Standardization and regulatory approvals foster broader market adoption.

Strategic Growth Opportunities in the ELISpot & FluoroSpot Assay Market

The ELISpot & FluoroSpot assay market is expanding across various applications, including disease diagnosis, vaccine development, and therapeutic monitoring. Opportunities for market players exist in enhancing research accuracy and supporting personalized medicine.

• Immunology Research: Critical for understanding immune mechanisms, improving treatment strategies.
• Infectious Disease Diagnostics: Enables sensitive detection for early diagnosis and monitoring.
• Cancer Immunotherapy: Evaluates patient responses, improving therapeutic efficacy.
• Vaccine Development: Accelerates candidate evaluation and deployment.
• Personalized Medicine: Offers customized therapeutic approaches based on immune profiling.

ELISpot & FluoroSpot Assay Market Driver and Challenges

Key drivers include technological advancements, rising disease prevalence, and increased clinical adoption, fostered by regulatory support. Challenges involve high costs, complex procedures, and stringent regulatory requirements.

• Drivers: Innovations and rising prevalence of diseases prompt demand for assay adoption.
• Challenges: High costs, complex protocols, and regulatory hurdles can limit adoption.

Country-Wise Outlook for the ELISpot & FluoroSpot Assay Market

The market showcases diverse adoption rates and technological progress across countries, shaped by healthcare investments and research initiatives.

• United States: Dominated by research funding and technological innovation, fostering market growth.
• China: Government-led biotech innovations drive rapid market expansion and adoption.
• Germany: Focus on integration into clinical diagnostics and vaccine research sustains growth.
• India: Rising healthcare investments and disease prevalence spur demand and innovation.
• Japan: Emphasis on personalized medicine and regulatory support strengthens market presence.

Companies Featured

• Mabtech
• Oxford Immunotec Global
• Cellular Technology Limited
• AID Autoimmun Diagnostika
• Merck KGaA
• Becton, Dickinson and Company
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Bio-Techne Corporation
• Dynex Technologies

For more information about this report visit https://www.researchandmarkets.com/r/owz9r4

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900